The evidence on peptides — delivered weekly. Subscribe free →

CGRP

low risk

Also: Calcitonin Gene-Related Peptide · α-CGRP · Vasodilatory neuropeptide

Strong Evidence Research Only

Reference entry for CGRP — the primary mediator of migraine pathogenesis. Not used as a therapeutic peptide itself; rather, it's the target for the monoclonal antibody drug class (erenumab, fremanezumab, galcanezumab) that have revolutionized migraine prevention. Understanding CGRP is essential for interpreting migraine therapeutics.

Molecular Weight
3789.3 Da
Formula
C146H244N42O44S
Common Dosing
Not used therapeutically; targeted by anti-CGRP antibodies
Category
therapeutic
Last Reviewed
2025-01-15

Reported Benefits

Migraine pathogenesis

Strong Evidence 320 studies

CGRP is the validated mechanistic target of multiple FDA-approved migraine drugs. Central to migraine biology.

Mechanism of Action

Potent vasodilatory neuropeptide; released from trigeminal nerve endings during migraine; binds CLR/RAMP1 receptor complex; promotes neurogenic inflammation and sensitization of pain pathways.

The Migraine Revolution

CGRP-targeted therapies (fremanezumab, erenumab, galcanezumab — all monoclonal antibodies) represent the first mechanism-specific migraine prevention class in history. Understanding CGRP physiology is foundational to this ~$5B annual market.

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Not applicable

Contraindications

  • •N/A

Primary Uses

Migraine pathophysiologyVasodilationPain signalingEducational reference

Related Peptides

vipspadin

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe CGRP?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.